Most Read Articles
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Jairia Dela Cruz, 23 Apr 2019
Rupatadine at either 10 or 20 mg delivers superior improvements in nasal and ocular symptoms of seasonal allergic rhinitis compared with placebo, with both doses well tolerated by adult and adolescent patients, according to the results of a phase III trial.
02 Dec 2019
Podcast: Associate Prof Pilar Garrido says osimertinib may be the best option in the first-line treatment of advanced NSCLC based on FLAURA OS results.
Pearl Toh, 20 Dec 2019
Faecal microbiota transplantation (FMT) is effective in reducing symptoms of irritable bowel syndrome (IBS), but having a “super-donor” is key, a study presented at UEG* Week has shown — highlighting the importance of donor selection for the success of FMT as a treatment for IBS.

Maribavir as good as valganciclovir for cytomegalovirus infection in transplant recipients

07 Nov 2019

Maribavir 400 mg twice daily appears to have comparable efficacy to valganciclovir at clearing cytomegalovirus (CMV) viraemia in transplant recipients, a study has found.

The phase II, open-label trial randomized 161 recipients of haematopoietic-cell or solid-organ transplants with CMV reactivation (1,000 to 100,000 DNA copies per millilitre) to receive maribavir at a dose of 400, 800 or 1,200 mg twice daily or the standard dose of valganciclovir for no more than 12 weeks.

Of the patients, 159 received treatment and 156 had postbaseline data available (117 in the maribavir groups and 39 in the valganciclovir group). Response to treatment within 3 weeks occurred in 62 percent of patients in the combined maribavir groups and 56 percent in the valganciclovir group. Within 6 weeks of treatment, 79 percent and 67 percent of patients had a response (risk ratio, 1.20, 95 percent confidence interval, 0.95–1.51). Treatment response did not differ among the maribavir dose groups.

CMV infection recurred within 6 weeks in two patients who received maribavir at a dose of 800 mg twice daily. Both patients developed T409M resistance mutations in CMV UL97 protein kinase.

Serious adverse events that occurred or worsened during treatment were higher in the maribavir group than in the valganciclovir group (44 percent vs 32 percent). Adverse events leading to trial discontinuation also occurred with greater frequency in the former (23 percent vs 12 percent). Gastrointestinal adverse events were common with maribavir, whereas neutropaenia was reported more frequently with valganciclovir.

Maribavir, especially given its unique mechanism of action and evidence suggesting a lack of myelosuppression, should be explored further in patients who have undergone transplantation, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Jairia Dela Cruz, 23 Apr 2019
Rupatadine at either 10 or 20 mg delivers superior improvements in nasal and ocular symptoms of seasonal allergic rhinitis compared with placebo, with both doses well tolerated by adult and adolescent patients, according to the results of a phase III trial.
02 Dec 2019
Podcast: Associate Prof Pilar Garrido says osimertinib may be the best option in the first-line treatment of advanced NSCLC based on FLAURA OS results.
Pearl Toh, 20 Dec 2019
Faecal microbiota transplantation (FMT) is effective in reducing symptoms of irritable bowel syndrome (IBS), but having a “super-donor” is key, a study presented at UEG* Week has shown — highlighting the importance of donor selection for the success of FMT as a treatment for IBS.